• ACCENT trial shows positive results for narmafotinib in pancreatic cancer
• Discontinued AMPLICITY trial due to high toxicity of FOLFIRINOX
• Discussions with FDA for Phase 2b/3 study underway
• Raised $27.5 million to support ongoing development

Amplia Therapeutics Ltd's Annual Report for the financial year ending 31 March 2026 highlights significant progress in clinical development, particularly with the ACCENT trial evaluating narmafotinib in combination with standard chemotherapy for pancreatic cancer. The trial demonstrated encouraging results, including a confirmed objective response rate of 36% and median progression-free survival of 7.7 months. However, the AMPLICITY trial, which combined narmafotinib with a more aggressive chemotherapy regimen, was discontinued due to high toxicity. The company is now focusing on the ACCENT trial and exploring new combination approaches. Regulatory progress includes positive feedback from the FDA on the design of a planned registration-enabling trial. Financially, Amplia raised $27.5 million to support ongoing development activities.

Amplia Therapeutics is planning a registration-enabling study with the FDA and exploring new combination approaches for narmafotinib.